An interventional study of Remifentanil and Propofol anesthesia in Drug Usage, sponsored by Ajou University School of Medicine. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-09.
Sponsored by Ajou University School of Medicine · Not applicable, Interventional, and Treatment
The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
Ajou University School of Medicine is the lead sponsor of 171 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
Drug: Remifentanil · Drug: Propofol anesthesia
The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
Also known as: Ultiva
Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
Also known as: Fresofol
Number of cough
Number of cough or a strong and sudden contraction of the abdomen during periextubation periods
Time frame: from end of surgery to 5 min after tracheal extubation
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ajou University School of Medicine